Anti-complement C1s antibodies and uses thereof
AssigneeBioverativ USA Inc.
InventorsPeter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. In some embodiments, such anti-complement C1s antibodies inhibit proteolytic activity of C1s. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
Claims21
One or more nucleic acids encoding an antibody that binds to complement C1s protein, wherein the antibody comprises:
- a light chain complementarity-determining region-1 (CDR-L1) sequence, a light chain complementarity-determining region-2 (CDR-L2) sequence, and a light chain complementarity-determining region-3 (CDR-L3) sequence of an antibody light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 15;
- and
- a heavy chain complementarity-determining region-1 (CDR-H1) sequence, a heavy chain complementarity-determining region-2 (CDR-H2) sequence, and a heavy chain complementarity-determining region-3 (CDR-H3) sequence of an antibody heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 16.
A method of producing a humanized antibody that binds to a complement C1s protein, the method comprising culturing a cell comprising one or more nucleic acids encoding the humanized antibody, wherein the humanized antibody comprises:
- a light chain complementarity-determining region-1 (CDR-L1) sequence, a light chain complementarity-determining region-2 (CDR-L2) sequence, and a light chain complementarity-determining region-3 (CDR-L3) sequence of an antibody light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 15;
- and
- a heavy chain complementarity-determining region-1 (CDR-H1) sequence, a heavy chain complementarity-determining region-2 (CDR-H2) sequence, and a heavy chain complementarity-determining region-3 (CDR-H3) sequence of an antibody heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO:
- 16, wherein the one or more nucleic acids are expressed in the cell and the humanized antibody is produced.
Dependencies are inferred from the claim text.